Comparative Pharmacology
Head-to-head clinical analysis: POMALIDOMIDE versus POMBILITI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALIDOMIDE versus POMBILITI.
POMALIDOMIDE vs POMBILITI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
POMBILITI (elafibranor) is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist that modulates lipid metabolism, inflammation, and fibrosis pathways. It reduces hepatic steatosis, inflammation, and ballooning by increasing fatty acid oxidation and decreasing lipogenesis.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
500 mg orally twice daily
None Documented
None Documented
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Deslanoside
"Pomalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePomalidomide + Acetyldigitoxin
"Pomalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Terminal elimination half-life is approximately 11 hours (range 6.5–19 h). Clinical context: supports twice-daily dosing with moderate accumulation; half-life prolonged in hepatic impairment.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Primarily biliary-fecal (77% of absorbed dose) and renal (23% unchanged) with enterohepatic recirculation.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent